{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:41:45Z","timestamp":1779154905558,"version":"3.51.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Our study aims at assessing the pre-clinical impact of the synergistic\nmechanism of Daptomycin (DAP) and Ceftaroline (CFT) on patients with Methicillin-Resistant Staphylococcus\naureus Bacteremia infections (MRSAB).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A systematic overview was conducted by searching PubMed, Oxford academic, and\nCochrane library up to June 2020. Study selection and data extraction: All English- language clinical\ntrials, in vitro studies, and case reports related to the synergistic drug therapy for MRSAB.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> In the case of MRSAB infections, we examined two different in vitro studies that showed\neffective synergism with DAP and CFT. The Minimum Inhibitory Concentration (MIC) range observed\nfor each is as follow: DAP 0.125-1 mg\/L, CFT 0.38-1 mg\/L, DAP + CFT 0.094-0.5 mg\/L,\nvancomycin (VAN) 0.75-2 mg\/L, VAN + CFT 0.25-2 mg\/L. DAP + CFT combination displayed\nthe most efficacy with the lowest MIC. The statistical analysis performed showed that DAP + CFT\nobtained significantly lower fractional inhibitory concentration (FIC) values (0.941 \u00b1 0.328) compared\nwith VAN + CFT. In vitro activities of regimens tested on DAP non-susceptibility and VAN\nintermediate after 96 hours showed DAP 8.29 \u00b1 0.03<jats:sup>a<\/jats:sup> log<jats:sub>10<\/jats:sub> CFU\/mL, VAN 6.82 \u00b1 0.04<jats:sup>a<\/jats:sup> log<jats:sub>10<\/jats:sub>\nColony Forming Unit (CFU)\/mL, CFT 4.63 \u00b1 0.19a log<jats:sub>10<\/jats:sub> CFU\/mL, DAP + CFT 1.15 \u00b1 0.20<jats:sup>b<\/jats:sup> log<jats:sub>10<\/jats:sub>\nCFU\/mL, VAN + CFT 3.18 \u00b1 0.49<jats:sup>a<\/jats:sup> log<jats:sub>10<\/jats:sub> CFU\/mL. (<jats:sup>a<\/jats:sup> meaning significantly different than DAP\nplus CFT, P&lt;equal to 0.001<jats:sup>b<\/jats:sup> meaning therapeutic enhancement combination was defined as \u2265 2\nlog<jats:sub>10<\/jats:sub> CFU\/ml reduction over the most active single agent). Based on these results, although DAP\nwas not susceptible, the Colony Forming Unit (CFU) for DAP and CFT had the best therapeutic results.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In vitro studies have shown that a combination DAP and CFT is more efficacious\nthan the combination of VAN and CFT in MRSA bacteremia infections. The synergic effects of\nDAP (bactericidal) and CFT (bactericidal) is statistically significant, in recent trials, warranting\npromising evidence for its use in complicated bacteremia infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574884715666210108103813","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T05:16:20Z","timestamp":1610342180000},"page":"296-299","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections"],"prefix":"10.2174","volume":"16","author":[{"given":"Jennyflore","family":"Eliazar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Larkin University College of Pharmacy, 18301 N. Miami Ave, Miami, FL33169, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevin","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Larkin University College of Pharmacy, 18301 N. Miami Ave, Miami, FL33169, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-7803","authenticated-orcid":true,"given":"Christiane","family":"Chbib","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Larkin University College of Pharmacy, 18301 N. Miami Ave, Miami, FL33169, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/190001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/190001\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/190001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T14:09:36Z","timestamp":1635775776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/190001\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574884715666210108103813","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}